Table 3.
Inhibition of cell–cell fusion by X5 and b12
| Envelope | Clade | Antibody
|
|
|---|---|---|---|
| X5 | b12 | ||
| UG037.8 | A | 29 | 24 |
| RW020.5 | A | 56 | 58 |
| US715.6 | B | 35 | 28 |
| HT593.1 | B | 20 | 39 |
| US005.11 | B | 24 | 47 |
| 89.6 | B | 100 | 100 |
| BR025.9 | C | 62 | 22 |
| ZR001.3 | D | 44 | 39 |
| TH022.4 | E | 17 | 34 |
| BR029.2 | F | 42 | 24 |
| BR019.4 | F/B | 62 | 63 |
| UG975.1 | G | 25 | 41 |
105 293 cells, transfected with plasmids encoding various HIV Envs under the control of T7 promoter and infected with recombinant vaccinia virus encoding T7 polymerase gene, were preincubated with X5 or IgG b12 at 100 μg/ml for 30 min at 37°C, and then mixed with 105 CEM-CCR5 cells infected with recombinant vaccinia virus encoding β-galactosidase gene. The extent of cell fusion was quantified colorimetrically 2 h after mixing the cells. The data are averages of duplicate samples and presented as % of fusion inhibition.